CRDFNasdaq

Cardiff Oncology, Inc.

Biological Products, (No Diagnostic Substances) · DE · CIK 1213037

Developing novel cancer therapies by targeting PLK1 inhibition with onvansertib and standard treatments

red 8-K · 90d

$105M

Market cap

$1.30

Last close

+2.4%

+4.0%

515K

Volume

Price · last 40 sessions-21.2%

May 4L $1.18 · H $1.94Jun 30

564

Total filings

Jun 11, 2026

Last filing

12/31

Fiscal year end

Similar companies

Comparable business profile · signals at a glance